Genetic testing can predict bladder cancer diagnosis years in advance

Published Date: 17 Mar 2023

Bladder cancer is not a rare disease. It is one of the 10 most common cancers in the UK and the 5th most common cancer in the European Union.

Read Full News

Latest News

Experimental Novartis Radiopharma Drug Shows Promise in Early Study

Novartis said on Sunday that early data from its experimental actinium-based drug showed signs of anti-tumour activity against prostate cancer, including in ⁠patients...

Vasectomy Reversal More Cost-Effective Than IVF

Most couples younger than 40 years can achieve pregnancy within typical $30,000-$40,000 employer fertility benefits with reversal, new research indicates.

US Judge Rejects Bayer Bid to Block Johnson & Johnson Prostate Cancer Drug Claims

A U.S. judge has rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that ⁠its multibillion-dollar drug cuts the risk of...

This Test Could Predict Incontinence Risk After HoLEP

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

Smartphone App Helps Delay Ejaculation

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

US FDA Approves Lantheus' New Prostate Cancer Imaging Formulation

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

Todays Updates

Timely ‘Nudges’ Help Spur Talks on Patient Care Goals

Simple well-timed prompts to clinicians and patients with advanced cancer can increase conversations around care goals, but clear documentation remains a challenge.

Todays Updates

Timely ‘Nudges’ Help Spur Talks on Patient Care Goals

Simple well-timed prompts to clinicians and patients with advanced cancer can increase conversations around care goals, but clear documentation remains a challenge.

Latest News

Novartis said on Sunday that early data from its experimental actinium-based drug showed signs of anti-tumour activity against prostate cancer, including in ⁠patients...

Most couples younger than 40 years can achieve pregnancy within typical $30,000-$40,000 employer fertility benefits with reversal, new research indicates.

A U.S. judge has rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that ⁠its multibillion-dollar drug cuts the risk of...

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

News All Time

FDA Approves New Treatment for Women's Simple UTIs.

Now available in the U.S. is an antibiotic that is widely used in other nations. s.

During the Accountable Care Meeting, CMS Officials were pressed on the topic of scanner fraud.

"We would appreciate it if you could give the matter more immediate attention," one ACO member said.

Nivolumab Plus Chemotherapy in First Line Approved for Bladder Cancer.

Combination decreased death risk by 22%.

King Charles III's Operation; COVID-19 Timeline Under Question; FDA Approvals Reach Record High.

The staff of MedPage Today has compiled health news and commentary from around the web.

Noninvasive Treatment Effective in Bladder Cancer That Is Not Muscle-Invasive.

An investigational intrusive solution produced a 79% complete response rate.

For Prostate Cancer at Intermediate Risk, SBRT Is Not Less Effective Than Conventional RT.

Similar results are obtained from treatment lasting one to two weeks as compared to therapy lasting up to seven and a half weeks.

The new first-line standard for advanced bladder cancer was produced by a landmark trial.

When compared to chemotherapy, enfortumab vedotin-pembrolizumab doubles OS and PFS.

Should Patients With Advanced Prostate Cancer Get Off the Active Surveillance Train?

Clearly defined rules are needed.

Even in those with HIV, a single dose of antibiotics was able to cure early syphilis.

In a randomized trial, one dosage showed no worse results than a triple-dose regimen.

Removing Cancer Survivors From Oncologic Treatment.

A new approach to care is required.

Cabazitaxel Lower-Dose Schedule Is Viable for Elderly Patients With mCRPC.

Neutropenia of grade three or above, with a twelve-fold reduction in neutropenic consequences.

AR-Pathway Inhibitor Switch for mCRPC is Superseded by Radionuclide Therapy.

With 177Lu-PSMA-617, the time to radiographic progression was doubled.

An RCT Supports HIF-2a Inhibition in Advanced RCC.

Belzutifan outperforms everolimus in the event of immunotherapy-TKI failure.

In severe cases of renal cell carcinoma, tyrosine kinase inhibitor activity is present.

Reactions to the "special medication" zanzalintinib in patients exposed and not exposed to cabozantinib.

CAR T-Cell Therapy for Renal Cell Carcinoma: "We're Not There Yet".

Possibility of standard of care following current therapies, but significant barriers still need to be overcome.

Finding New Routes to Improve Renal Cell Carcinoma Outcomes.

It is necessary to intervene at several stages of the cancer immunity cycle in order to build on recent successes.

Recommended News For You

First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.

Non-Hodgkin lymphomas that are indolent have been linked to psychological distress.

GFR-TKIs taken orally in cancer patients who have artery dissection and aneurysms.

Research identifies nearly 200 potential breast carcinogens in food packaging materials

In MDS at Lower Risk, Novel Therapy Diminished Transfusion Dependency.

Anticoagulation for 12 months has been found to improve outcomes in cancer patients with minor blood clots.

ctDNA Predicts Relapse in Locally Advanced Cervical Cancer

Recommended Articles For You

Targeting Oncology: Expanding Combinatorial Strategies by 2025 

Next-Generation Sequencing in Oncology: Unlocking the Future of Precision Medicine 

Tailoring the Immune Response: The Dawn of Personalized Vaccines in Cancer Immunotherapy 

Understanding Adenomyosis: The Role of Ultrasound in Diagnosis Introduction 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Stem Cell Selection Unneeded for SSc Transplant Therapy?

2.

Implant-based reconstruction linked to increased risk of breast lymphomas

3.

Radioligand Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer

4.

Scientists call into question safety of potential new anticancer treatment

5.

The discovery of drug combinations may increase the life expectancy of children with brain cancer.

1.

Modern Oncology Unveiled with Treatment Innovations and Personalized Cancer Care

2.

Beyond the Surface: Understanding the Silent Menace of Abdominal Hematomas

3.

The Statistical Imperative: Navigating Trends, Precision, and Innovation in Gynecologic Oncology 2025

4.

Empowering Lung Cancer Diagnosis Through the Synergy of Advanced Technologies and Artificial Intelligence

5.

Integrated Techniques in Oncology in the Digital Era

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

Efficient Management of First line ALK-rearranged NSCLC - Part IV

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V

3.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion

4.

The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot